By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Janssen Pharmaceutica, part of Johnson & Johnson's Janssen Pharmaceutical division, will develop assays on the Biocartis molecular diagnostics system, Biocartis said today.

Under the agreement, Janssen and J&J's Ortho-Clinical Diagnostics group will have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.